Newsroom

While innovation drove the early stages of cell therapy development, the industry is now transitioning to address the challenges of delivering these therapies to patients on a large scale. Josh Ludwig of ScaleReady emphasizes the importance of standardized workflows that are scalable and easily automated to improve efficiency.

Automation is necessary for the future of CGT manufacturing to reduce contamination risk. However, as Jenny Stjernberg of ScaleReady highlights in this BioProcess International article, premature automation without simplifying processes can lead to longer timelines, increased risk, and financial strain.

Industry experts, including Jenny Stjernberg, Ph.D., Commercial Director, EMEA, discuss which conventional industry wisdom they believe is misguided, outdated, or just plain wrong with Pharma's Almanac. Jenny discusses how many developers have too-literally retained the conventional wisdom that for cell-based therapies "process is product."

Cell therapies show remarkable potential in treating challenging lymphomas, as demonstrated by real-world data. But companies may run out of funds before reaching milestones due to factors like inefficient manufacturing, facility costs, and difficulties scaling processes. Alaina Schlinker, Ph.D., Senior Manager, Field Applications Support, ScaleReady, discusses how ScaleReady's platforms aim to help developers reach clinical milestones quickly and cost-effectively.

Drug Discovery World asked Advanced Therapies Europe attendees: What is most important to scale from discovery to commercialization of cell and gene therapies (CGTs)? ScaleReady’s Josh Ludwig answers.

In an exclusive interview with RegMedNet, Jenny Stjernberg discusses the crucial role of scalability in advancing groundbreaking therapies. Stjernberg emphasizes the importance of preserving flexibility while scaling up cell therapy manufacturing approaches.

Watch the roundtable discussion from Medicine Maker featuring experts from ScaleReady, Terumo Blood and Cell Technologies, Orgenesis, and BioBridge Global.

In this edition of Pharma's Almanac, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss increased innovation and adoption of artificial intelligence (AI) and machine learning in biopharma.

In this expert roundtable, David McCall, Senior Editor, BioInsights, speaks to Anastasiya Smith, Senior Director of R&D, CellReady; Josh Ludwig, Global Director, Commercial Operations, ScaleReady; and David Hermanson, Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-Techne.

Terumo’s Stuart Gibb, Ph.D., at Terumo Blood and Cell Technologies, is joined by Nisha C. Durand, PhD, at Mayo Clinic and Matthew M. Hewitt, B.A. Ph.D., Charles River.